Tag: BIO CEO & Investor Conference
Despite Low Funding, Biotech Productivity Remains High In 2013
At the 2013 BIO CEO & Investor Conference, John Milligan, President and COO of Gilead …
Onyx CEO One of 25 Most Influential People in Biopharm Today According to FierceBiotech
After a stellar year, as evidenced by inclusion in the second annual FierceBiotech “25 Most …
How to Survive the Patent Cliff: Eli Lilly’s CEO at the BIO CEO & Investor Conference
Like a number of companies, Eli Lilly is confronting a wave of patent expirations called …
Word on the Street – Biotech Stocks Only Have Room to Go Up
The Opening Lunch Plenary at this year’s BIO CEO & Investor Conference was a lively …
Celgene CEO on New Multiple Myeloma Drug Approvals
Following on the heels of two big announcements in February, Celgene CEO Robert Hugin (one …
The Year Ahead for Business Development Events
2013 is officially here (insert stale End-of-the-World joke). And as such, planning has been in …
Industry Outlook in Anticipation of the 2012 BIO International Convention
This month, BIO wrapped the 14th Annual CEO & Investor Conference in New York City …
BIO CEO 2012 Opening Remarks
The 14th Annual BIO CEO & Investor Conference started with a busy turnout Monday at …
Value Drivers Under the Influence – How Licensing and Key Events Affect Valuation
The Tuesday plenary luncheon at the 2012 BIO CEO & Investor Conference featured a panel …
Fireside Chat with Dr. Mikael Dolsten
Day two of the BIO CEO & Investor Conference kicked off with a Fireside Chat …